These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 16879212)

  • 1. Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo.
    Shelat SG; Smith P; Ai J; Zheng XL
    J Thromb Haemost; 2006 Aug; 4(8):1707-17. PubMed ID: 16879212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel flow-based assay reveals discrepancies in ADAMTS-13 inhibitor assessment as compared with a conventional clinical static assay.
    Grillberger R; Gruber B; Skalicky S; Schrenk G; Knöbl P; Plaimauer B; Turecek PL; Scheiflinger F; Rottensteiner H
    J Thromb Haemost; 2014 Sep; 12(9):1523-32. PubMed ID: 25040659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism underlying severe deficiency of plasma ADAMTS-13 activity in immune thrombotic thrombocytopenic purpura.
    Zheng XL
    J Thromb Haemost; 2024 May; 22(5):1358-1365. PubMed ID: 38360215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathogenicity of Anti-ADAMTS13 Autoantibodies in Acquired Thrombotic Thrombocytopenic Purpura.
    Thomas MR; de Groot R; Scully MA; Crawley JT
    EBioMedicine; 2015 Aug; 2(8):942-52. PubMed ID: 26425702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FRETS-VWF73 rather than CBA assay reflects ADAMTS13 proteolytic activity in acquired thrombotic thrombocytopenic purpura patients.
    Mancini I; Valsecchi C; Lotta LA; Deforche L; Pontiggia S; Bajetta M; Palla R; Vanhoorelbeke K; Peyvandi F
    Thromb Haemost; 2014 Aug; 112(2):297-303. PubMed ID: 24740645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutralization of inhibitory antibodies and restoration of therapeutic ADAMTS-13 activity levels in inhibitor-treated rats by the use of defined doses of recombinant ADAMTS-13.
    Plaimauer B; Schiviz A; Kaufmann S; Höllriegl W; Rottensteiner H; Scheiflinger F
    J Thromb Haemost; 2015 Nov; 13(11):2053-62. PubMed ID: 26340698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autoantibodies enhance ADAMTS-13 clearance in patients with immune thrombotic thrombocytopenic purpura.
    Underwood MI; Alwan F; Thomas MR; Scully MA; Crawley JTB
    J Thromb Haemost; 2023 Jun; 21(6):1544-1552. PubMed ID: 36813118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of N-glycan mediated shielding of ADAMTS-13 on the binding of pathogenic antibodies in immune thrombotic thrombocytopenic purpura.
    Postmus T; Graça NAG; Ferreira de Santana J; Ercig B; Langerhorst P; Luken B; Joly BS; Vanhoorelbeke K; Veyradier A; Coppo P; Voorberg J
    J Thromb Haemost; 2023 Dec; 21(12):3402-3413. PubMed ID: 37633643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura.
    Scheiflinger F; Knöbl P; Trattner B; Plaimauer B; Mohr G; Dockal M; Dorner F; Rieger M
    Blood; 2003 Nov; 102(9):3241-3. PubMed ID: 12855569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical utility of ADAMTS13 activity, antigen and autoantibody assays in thrombotic thrombocytopenic purpura.
    Starke R; Machin S; Scully M; Purdy G; Mackie I
    Br J Haematol; 2007 Feb; 136(4):649-55. PubMed ID: 17367414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura.
    Jian C; Xiao J; Gong L; Skipwith CG; Jin SY; Kwaan HC; Zheng XL
    Blood; 2012 Apr; 119(16):3836-43. PubMed ID: 22289888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurement and prevalence of circulating ADAMTS13-specific immune complexes in autoimmune thrombotic thrombocytopenic purpura.
    Lotta LA; Valsecchi C; Pontiggia S; Mancini I; Cannavò A; Artoni A; Mikovic D; Meloni G; Peyvandi F
    J Thromb Haemost; 2014; 12(3):329-36. PubMed ID: 24354764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Von Willebrand factor-cleaving protease (ADAMTS-13) activity in thrombotic microangiopathies: diagnostic experience 2001/2002 of a single research laboratory.
    Studt JD; Kremer Hovinga JA; Alberio L; Bianchi V; Lämmle B
    Swiss Med Wkly; 2003 Jun; 133(23-24):325-32. PubMed ID: 12923683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ADAMTS-13 conformation influences autoimmune recognition in immune thrombotic thrombocytopenic purpura.
    Underwood MI; Thomas MR; Scully MA; Crawley JTB
    J Thromb Haemost; 2024 Apr; 22(4):1069-1079. PubMed ID: 38160729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ADAMTS-13 plasma level determination uncovers antigen absence in acquired thrombotic thrombocytopenic purpura and ethnic differences.
    Feys HB; Liu F; Dong N; Pareyn I; Vauterin S; Vandeputte N; Noppe W; Ruan C; Deckmyn H; Vanhoorelbeke K
    J Thromb Haemost; 2006 May; 4(5):955-62. PubMed ID: 16689741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Expression of vWF73 and VWF114 fragments of von Willebrand factor A2 domain and their utilization in detecting ADAMTS13 activity].
    Zhang JY; Ma ZN; Dong NZ; Hu LP; Su J; Wang ZY; Ruan CG
    Zhonghua Xue Ye Xue Za Zhi; 2011 May; 32(5):337-41. PubMed ID: 21729605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ADAMTS-13 antigen and activity levels in thrombocytopenic disorders including thrombotic thrombocytopenic purpura in Kuwait.
    Al-Awadhi AM; Jadaon MM; Al-Jafar HA; Al-Wazzan HJ
    Acta Haematol; 2011; 125(3):160-6. PubMed ID: 21196718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel, semi-automated, 60-min-assay to determine von Willebrand factor cleaving activity of ADAMTS-13.
    Kostousov V; Fehr J; Bombeli T
    Thromb Res; 2006; 118(6):723-31. PubMed ID: 16430944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ADAMTS13 and anti-ADAMTS13 autoantibodies in thrombotic thrombocytopenic purpura - current perspectives and new treatment strategies.
    Tersteeg C; Verhenne S; Roose E; Schelpe AS; Deckmyn H; De Meyer SF; Vanhoorelbeke K
    Expert Rev Hematol; 2016; 9(2):209-21. PubMed ID: 26581428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of the ADAMTS-13 missense mutation R1060W in late onset adult thrombotic thrombocytopenic purpura.
    Camilleri RS; Cohen H; Mackie IJ; Scully M; Starke RD; Crawley JT; Lane DA; Machin SJ
    J Thromb Haemost; 2008 Feb; 6(2):331-8. PubMed ID: 18031293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.